In the preliminary analysis of the ISEL trial.

In the meantime, AstraZeneca believes it is premature to Iressa Compassionate Use program include include new patients and co-operativeISEL record is rated as the company remains convinced by the evidence that Iressa benefit in patients with NSCLC provides. The status of all ongoing AstraZeneca -sponsored trials in NSCLC is currently being reviewed. Investigator and co-operative groups have been informed, are all attempts to open recruitment on a study by on a study by study. Studies in other tumor types will continue..

AstraZeneca is a major international healthcare business in the research, development, manufacture and marketing of prescription pharmaceuticals and healthcare services busy. It is one of the world’s leading pharmaceutical companies with sales of more than $ 18800000000 and leading positions in sales of gastrointestinal, oncology, cardiovascular, neuroscience and respiratory products. FTSE4Good Index.ed in the Dow Jones Sustainability Index as well the FTSE4Good Index.The British Medical Association in Northern Ireland compared university top-up fees.responding to the BMA Medical Students Committee in Northern Ireland in detail so a consultation paper suggests the introduction by variable remuneration Northern Ireland. This document was today, April 2004 to. Barry Gardiner MP, Ministerial for Employment and Learning. However, the BMA say be to the introduction of top-up fees and to such action, In If is introduced:.

– undermine the policies of the attracting students into the medical on a broad social background of.

Press Release Date: Thursday.